Depletion of nonmalignant lymphocytes when venetoclax is combined with ibrutinib. Lymphocyte analysis in PB of patients at baseline, after preinduction with ibrutinib, and after 1 year of treatment with venetoclax-ibrutinib (n = 10) by flow cytometry. Absolute number of B cells (A) and CD4⁺ and CD8⁺ T cells (B) in PB. (C) Absolute number of NK (CD56^bright and CD16⁺) cells in PB. (D) Ratio of CD56^bright (CD56^brightCD16⁻) cells vs CD56^dim (CD56^dimCD16⁺) cells. Horizontal lines indicate reference values. *P < .05, **P < .01, 1-way ANOVA followed by Sidak’s multiple-comparisons test.